ACCPL Stock Overview

Manufactures and sells pharmaceutical products in India. More details

ACCPL fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	2/6
Financial Health	3/6
Dividends	0/6

Rewards

Price-To-Earnings ratio (21.5x) is below the Indian market (27.8x)

Earnings grew by 3629.8% over the past year

Risk Analysis

Debt is not well covered by operating cash flow

Shares are highly illiquid

High level of non-cash earnings

Does not have a meaningful market cap (₹833M)

+ 2 more risks

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Accretion Pharmaceuticals Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Accretion Pharmaceuticals
Historical stock prices
Current Share Price	₹74.90
52 Week High	₹82.95
52 Week Low	₹74.90
Beta	0
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-9.70%

Recent updates

Shareholder Returns

	ACCPL	IN Pharmaceuticals	IN Market
7D	n/a	-0.04%	-0.2%
1Y	n/a	13.1%	2.2%

Return vs Industry: Insufficient data to determine how ACCPL performed against the Indian Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how ACCPL performed against the Indian Market.

Price Volatility

Is ACCPL's price volatile compared to industry and market?
ACCPL volatility
ACCPL Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	7.0%
Market Average Movement	7.0%
10% most volatile stocks in IN Market	9.6%
10% least volatile stocks in IN Market	4.7%

Stable Share Price: ACCPL's share price has been volatile over the past 3 months compared to the Indian market.

Volatility Over Time: Insufficient data to determine ACCPL's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2012	n/a	Vivek Ashok Patel	www.accretionpharma.com

Accretion Pharmaceuticals Limited manufactures and sells pharmaceutical products in India. Its products include antibiotic, antibacterial, antifungal, anti-inflammatory, anti-spasmodic, antihistamine, antiallergy, anticough, anticold, antiulcer, gastrointestinal, antacid, anti-diabetic, cardiac, anti-hypertensive, psychotropic, memory enhancer, vitamins, supplements, and other products; and external preparation, oral powder, effervescent formulation, and nutraceutical products, as well as formulations for brain and memory care, neuron care, UTI care, cardiac care, liver care, protein supplement, pediatric care, GIT care, joint and bone care, immunity booster, gynec care, hair and skin care, nail care, and infertility, and PCOS care. The company offers its products in the form of tablets, capsules, oral liquids, ointments, creams, gels, lotions, medicated shampoos, mouthwashes, dusting powders, sachets, dry syrups, etc for direct sales, loan licence and/or contract manufacturing.

Accretion Pharmaceuticals Limited Fundamentals Summary

How do Accretion Pharmaceuticals's earnings and revenue compare to its market cap?
ACCPL fundamental statistics
Market cap	₹832.59m
Earnings (TTM)	₹38.75m
Revenue (TTM)	₹339.39m

21.5x

P/E Ratio

2.5x

P/S Ratio

Is ACCPL overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ACCPL income statement (TTM)
Revenue	₹339.39m
Cost of Revenue	₹222.69m
Gross Profit	₹116.69m
Other Expenses	₹77.94m
Earnings	₹38.75m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	3.49
Gross Margin	34.38%
Net Profit Margin	11.42%
Debt/Equity Ratio	252.1%

How did ACCPL perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/25 15:06
End of Day Share Price	2025/05/23 00:00
Earnings	2024/03/31
Annual Earnings	2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Accretion Pharmaceuticals Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Accretion Pharmaceuticals NSEI:ACCPL Stock Report